SKU: M091  / 
    CAS Number: 59-05-2

    Methotrexate, EvoPure®

    $0.00

    Methotrexate, EvoPure® is a highly pure form of Methotrexate that is free of toxic impurities and has been fully characterized by FTIR, HNMR, HPLC, and mass spectrometry.  It is suitable as an ancillary material in upstream bioprocessing.

    Methotrexate is a selective agent for dihydrofolate reductase (DHFR)- transfected cells, and acts as a nucleic acid synthesis inhibitor.  It also has immunosuppressive effects for rheumatoid arthritis research and exhibits anti-cancer properties.  

    We also offer:

    • Methotrexate sodium salt (M031)
    • Methotrexate, EvoPure® (M091)

    This product is considered a dangerous good. Quantities above 1 g may be subject to additional shipping fees. Please contact us for questions.

    Mechanism of ActionMethotrexate acts as an allosteric inhibitor of dihydrofolate reductase (DHFR), an enzyme involved in the folic acid metabolic pathway. Folic acid is essential in cells because it is required for thymidine and purine synthesis. Methotrexate therefore acts as a nucleic acid synthesis inhibitor.
    Eukaryotic Cell Culture Applications

    Methotrexate is commonly used in the dihydrofolate reductase (DHFR) selection system as a selection antibiotic to select for DHFR- deficient cells during transfection. Methotrexate inhibits DHFR; however, cells that overproduce DHFR produce more recombinant protein and can tolerate higher concentrations of Methotrexate.

    Mammalian cells used in biopharma manufacturing such as CHO cells may exhibit toxicity to USP-grade material.  Our Methotrexate, EvoPure® has been purified to remove toxic impurities.  If you have unique specifications for your system, please contact us.

    Cancer ApplicationsMethotrexate acts as a chemotherapeutic agent by inhibiting nucleic acid synthesis in cancer cells.
    Insect Biology ApplicationsMethotrexate is effective against pyrimethamine-resistant Plasmodium vivax malaria parasites.
    Molecular FormulaC20H22N8O5
    Identification
    • FTIR - Conforms
    • Mass - Conforms
    • HNMR - Conforms
    ReferencesFairbanks, LD et al (1999)  Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: A metabolic basis for efficacy in rheumatoid arthritis? Biochem. J 342 (1):143-52

    Kingston RE, Kaufman RJ, Bebbington CR and Rolfe MR (2002)  Amplification using CHO cell expression vectors. Curr. Protoc. Mol. Biol. Chapter 16:Unit 16.23  PMID 18265304

    Maleki H et al (2017)  Methotrexate-loaded PLGA nanoparticles: Preparation, characterization and their  cytotoxicity effect on human glioblastoma U87MG cells. Med. Nano. Res. 4(1):020